Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre

Antoniou, Christina; Stefanaki, Irene; Stratigos, Alexandros; Moustou, E; Vergou, Theognosia; Stavropoulos, P.G.; Avgerinou, Georgia; Rigopoulos, Dimitrios; Katsambas, Andreas

doi:10.1111/j.1365-2133.2009.09578.x

Cited by 13 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies on the long‐term effects of biological treatment in psoriasis have predominantly been extensions of clinical trials focusing on single agents. Also, earlier real‐world studies on the long‐term effects of biological treatment and previous register‐based studies focused on single agents. In contrast, the motivation of the present study was to adopt a patient perspective focusing on the outcomes for patients rather than on specific agents, allowing patients to switch between treatments, which results in a less selected patient group.…”

Section: Discussionmentioning

confidence: 99%

Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol‐5D response of biological treatment in psoriasis: 10 years of real‐world data in the Swedish National Psoriasis Register

2018

View full text Add to dashboard Cite

Summary Background Few studies have analysed the long‐term effects of biological treatment in psoriasis. PsoReg, the Swedish national register for systemic psoriasis treatment, started in 2006 and now includes 10 years of real‐world data on the effectiveness of biological treatment. Objectives To analyse the long‐term real‐world outcome data of patients who are biologically naïve with moderate‐to‐severe psoriasis after switching to biological treatment. Methods An observational study of patients who are biologically naïve with at least one registration of outcome before switching to biological treatment while included in PsoReg and at least one follow‐up visit. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol‐5D (EQ‐5D) values were analysed at 3–5 months, 6–11 months and at least once after ≥ 1 year, up to 9 years after the switch to biological treatment. Results In total, 583 patients fulfilled the inclusion criteria. Of these, 399, 395 and 373 patients had observed outcome data beyond 1 year on the PASI, DLQI and EQ‐5D, respectively, and 164, 168 and 152, respectively, were observed in at least three time periods after the switch. Significant (P < 0·01) improvement in PASI, DLQI and EQ‐5D scores was observed 3–5 months after the switch and sustained under the whole observation period. The mean PASI, DLQI and EQ‐5D changed from 13·5 ± 9·1, 9·0 ± 8·1 and 0·74 ± 0·22, respectively, before the switch, to 4·0 ± 3·5, 3·7 ± 4·7 and 0·79 ± 0·21, respectively, 1–5 years after the switch. Conclusions Biological treatment, as used in clinical practice, shows a stable long‐term effectiveness in all the measured dimensions, PASI, DLQI and EQ‐5D.

show abstract

Section: Discussionmentioning

confidence: 99%

Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol‐5D response of biological treatment in psoriasis: 10 years of real‐world data in the Swedish National Psoriasis Register

2018

View full text Add to dashboard Cite

show abstract

“…In our series, the PASI75 response rates (73% at week 24, 65% at week 52, intent-to-treat analysis), were consistent with those of the EXPRESS 1 (82% at week 24 and 61% at week 50 respectively) and the EXPRESS II 2 (76% at week 22 and 55% at week 50 respectively) clinical trials. Nevertheless, 59% of patients in our cohort discontinued treatment after a median of 12 months [interquartile range (IQR) [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. Loss of efficacy, alone or in combination with infusion reaction, accounted for most cases (21 of 37, or 57%) of treatment discontinuation.…”

Section: Discussionmentioning

confidence: 99%

Long‐term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions

Spertino

López‐Ferrer

Vilarrasa

et al. 2013

Acad Dermatol Venereol

View full text Add to dashboard Cite

This retrospective review of a cohort of patients with moderate-to-severe psoriasis treated with infliximab in daily practice shows that the PASI75 response rates at 24 and 52 weeks of treatment are similar to those of the pivotal studies, but 37 courses of treatment (59%) had to be discontinued after a median of 12 months. The major cause for discontinuation was loss of response, in 18 cases. Combination treatment, obesity and infusion reactions were found to be predictors of drug survival.

show abstract

“…Nevertheless, an official Greek language translation is available and this version has already been successfully applied in studies conducted in the Greek population [30]. Moreover, there is extensive experience concerning the application of DLQI to patients with urticaria [18,23], and the DLQI is by far the most frequently applied HRQoL instrument in the field of dermatology.…”

Section: Discussionmentioning

confidence: 99%

Disease Activity Only Moderately Correlates with Quality of Life Impairment in Patients with Chronic Spontaneous Urticaria

Koti¹,

Weller²,

Makris³

et al. 2013

Dermatology

View full text Add to dashboard Cite

Background: The impact of chronic spontaneous urticaria (CSU) on health-related quality of life (HRQoL) is widely held to be mainly influenced by disease activity and comorbidities. Objective: To assess the correlation between disease activity and HRQoL impairment by using validated disease-specific instruments. Methods: The Chronic Urticaria Quality of Life Questionnaire (CU-Q₂oL) was translated into Greek and subsequently applied to 110 CSU patients along with the Dermatology Life Quality Index and the Urticaria Activity Score. After the validity and reliability of the Greek CU-Q₂oL had been determined, we assessed the relation between disease activity and HRQoL impairment by computing correlations as well as by performing multiple regression analysis. Results: Exploratory factor analysis revealed a six-scale structure of the Greek CU-Q₂oL that explained 67.9% of its total variance. The internal consistency was satisfactory with Cronbach's α >0.7. Disease activity was the only predictor of quality of life impairment, but it only moderately correlated with the CU-Q₂oL total score (r = 0.40, p < 0.0001). Conclusion: Our results suggest that there are additional factors to disease activity that are responsible for the pronounced reduction of HRQoL in CSU, and this supports the recommendation to assess and monitor both disease activity and quality of life in CSU patients.

show abstract

Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre

Cited by 13 publications

References 20 publications

Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol‐5D response of biological treatment in psoriasis: 10 years of real‐world data in the Swedish National Psoriasis Register

Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol‐5D response of biological treatment in psoriasis: 10 years of real‐world data in the Swedish National Psoriasis Register

Long‐term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions

Disease Activity Only Moderately Correlates with Quality of Life Impairment in Patients with Chronic Spontaneous Urticaria

Contact Info

Product

Resources

About